Phase 2 N=389 Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension
Hypertension
Primary: Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) — -11.53; -10.98; -12.45; -3.69 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,099 Evaluating the Relationship Between Inflammation, Genetics, and Stress in the Development of High Blood Pressure
Hypertension
Primary: Change in Urinary Sodium Excretion (UNaV) — 11.8; 15.2 pg/ml
N/A N=5 HIRREM for Stage 1 Primary Hypertension
Hypertension · Blood Pressure · Cardiovascular Diseases
Primary: Change From Baseline in Blood Pressure, as Measured by an Automated Oscillometric Blood Pressure Device. — -3.00; -6.67; -6.00; -7.67 mmHg
Phase 2 N=524 A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension
Essential Hypertension
Primary: Core Period: Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8 Last Observation Carried Forward (LOCF), as Measured by Office Blood…
N/A N=17 Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment
Obstructive Sleep Apnea · Resistant Hypertension · Hyperaldosteronism
Primary: Severity of Obstructive Sleep Apnea — -18.3; 7.0 events/hour
N/A N=35 Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension
Essential Hypertension
Primary: The Number of Patients for Whom Each Drug is Selected as the Preferred Therapy — 16; 8; 4 Participants
Phase 2 N=14 The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension
Hypertension
Primary: Muscle Sympathetic Nerve Activity at Rest — 41; 43.8 bursts/minute
N/A N=125 Self-Management and Resilience Trajectories in African American Adults With Hypertension
Hypertension · Self-Management · Quality of Life
Primary: Systolic Blood Pressure — 138.35; 135.56 mmHg — p=0.0050
Phase 2 N=59 Tissue Sodium in Pre-hypertensive Patients
Hypertension
Primary: Change in Tissue Sodium Concentration Measured Using Sodium Magnetic Resonance Imaging (NaMRI) — -0.202; 0.430; -1.745; -0.407 mmol/L
Phase 3 N=278 A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)
Hypertension
Primary: Percentage of Participants Who Experienced an Adverse Event When Receiving MK-0954A (L100/H12.5) During Study (8-week Double-blind and/or 44-week Open-label Extension)…
N/A N=92 Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events
Systemic Arterial Hypertension · Hypertension Resistant to Conventional Therapy · Myocardial Infarction
Primary: Strokes, Either Fatal or Nonfatal — 24; 7 participants — p=0.19
N/A N=574 Targeting of UnControlled Hypertension in Emergency Department
Hypertension · Cardiovascular Diseases · Vascular Diseases
Primary: Mean Systolic Blood Pressure (SBP) Difference at 6 Months Post-intervention Compared to Usual Care. — -9.2; -14.0 mmHg
Phase 3 N=114 Irbesartan and Atenolol in Hypertensive Heart Disease
Hypertension
Primary: Changes in Left Ventricular Mass Index — -1; -9; -6; -14 g/m^2
Phase 3 N=336 MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)
Hypertension
Primary: Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) — -8.7; -3.6 mmHg — p=<.001
N/A N=75 Understanding the Exercise-Hypertension Paradox
Hypertension
Primary: Blood Pressure — 103; 106; 94; 101 mmHg
N/A N=591 Hypertension Intervention Nurse Telemedicine Study (HINTS)
Hypertension
Primary: Estimated Percentage of Participants in Blood Pressure Control at Baseline — 61; 59; 53; 64 % of particpants w/ controlled BP
Phase 2 N=490 Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
Essential Hypertension
Primary: Change From Baseline to End of Double-blind Treatment in Sitting Diastolic Blood Pressure at Trough — 97.5; 97.8; 97.7; 97.8 mmHg — p=<0.001
Phase 2 N=1,328 Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
Hypertension
Primary: Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) — -9.97; -12.92; -13.63; -9.14 mmHg
Phase 2 N=7 Mechanisms of Refractory Hypertension (Reserpine)
Refractory Hypertension
Primary: Change Ambulatory Systolic Blood Pressure — -29.3 mmHg
Phase 3 N=2,694 Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension
Hypertension
Primary: Pairwise Comparison of Aliskiren/Amlodipine 150/5 mg vs. Aliskiren 150 mg on Change in Mean Sitting Diastolic Blood Pressure (msDBP) — -7.99; -13.98 mm Hg — p=<0.001
Phase 3 N=261 Obese Hypertension Study (0954-315)
Hypertension
Primary: Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8 — -12.1; -6.8 mm Hg
N/A N=123 Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients
Hypertension · High Blood Pressure · Ventricular Hypertrophy
Primary: Clinically Significant Difference in Blood Pressure Lowering, Health Status and Quality of Life — -3.3; -4.9 mm Hg
Phase 3 N=1,010 Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension
Essential Hypertension
Primary: Change in Mean Trough Sitting Diastolic Blood Pressure — -11.16; -10.45 mm Hg — p=0.2648
Phase 3 N=932 Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
Essential Hypertension
Primary: Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to Week 8 Endpoint — -10.3; -6.6 mmHg
Phase 3 N=341 A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension
Essential Hypertension
Primary: Number of Participants Who Experience at Least One Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 289; 20 Participants
Phase 2 N=22 Safety Study of RMJH-111b to Treat Essential Hypertension
Essential Hypertension
Primary: Safety and Tolerability of RMJH-111b Compared to Placebo Based on Treatment Emergent Adverse Events (TEAEs) — 5; 1; 0; 0 Participants
N/A N=718 Azilsartan Circadian and Sleep Pressure
Hypertension
Primary: Change in Nocturnal Systolic Blood Pressure Level — -12.6; -17.5 mmHg
N/A N=56 Mindfulness Based Stress Reduction for High Blood Pressure
Hypertension
Primary: SBP — 130.2; 128.8 mm Hg
Phase 2 N=200 Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension
Hypertension, Renal
Primary: Change From Baseline in Office-measured Systolic Blood Pressure (SBP) at Study Week 8 Compared to Placebo — -4.10; -11.3; -11.07; -5.63 mmHg
N/A N=146 The Effect of Pre-discharge Blood Pressure of Patients With Asymptomatic Severe Hypertension in Emergency Department
Hypertension · Emergencies · Asymptomatic Conditions
Primary: Number of Participants Who Died Within 7 Days After Discharge From the Emergency Department — 0; 0 participants